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SUMMARY 
15 schizophrenic patients were treated with dl-propranolol in a 4 week open study. Dosage was 
gradually increased over a period of 17 days to 1920 mg/day. Improvements were rated on Thought Disorder 
Scores (A & B) of the MBPRS and GPRS subscale for schizophrenia. Majority of the patients showed a 50% 
improvement in terms of their residual scores by the 4th week of treatment and the side effects experienced 
were minimal-
Clinical reports over the past decade 
have amply exemplified the role of beta 
blockers in a variety of psychiatric conditions. 
Promising results have been observed in 
psychotic conditions when beta blockers, 
especially propranolol is administered in 
high doses. The preliminary observations of 
Atsmon et al. (1970), have triggered of a se-
ries of open as well as controlled investiga-
tions into the therapeutic potential of propra-
nolol. In a clinical trial of propranolol in 13 
patients (including 9 schizophrenics) a quick 
symptomatic improvement was observed 
when doses as high as 5, 800 mg/day were 
used. Yorkston et al. (1974; 1976; 1977; 
1978) investigated the antipsychotic effects 
of this compound in 55 schizophrenics with 
florid features. 28 of these lost their schizo-
phrenic symptoms, and 17 of those who 
improved were on propranolol alone. When 
compared against placebo in 14 patients in a 
double blind manner (Yorkston et al., 1977), 
the propranolol group was significantly bet-
ter than placebo when the sum of the dvree 
thought disorder scales were considered after 
the 12th week (p<0.035). Improvement in 
the thought disorder scale continued even 
after the 12 week study. Although the best 
results have been observed in those ill for 
less than 1 year (Yorkston et al., 1976), 15 
out of 38 of this series who remitted com-
pletely were ill from 1 -30 years. Patients in 
this series usually showed a gradual improve-
ment, with hallucinations stopping before 
secondary delusions and the latter remitting 
more often gradually than abruptly. Worsen-
ing on withdrawal of propranolol in 20 
chronic schizophrenics was obseived in an 
unpublished study by Yorkston and col-
leagues, with development of thought dis-
turbance, delusions, and abnormal activity 
levels. Auriol et al. (1972) have also re-
ported improvement in thought distur-
bances in 30 psychotics on low doses of 
pindolol (7.5—45 mg). Lindstrom and 
Persson (1980) studied the effect of pro-
pranolol in 12 chronic schizophrenics (dose 
1280-1920 mg/day) in a double blind study. 
They recorded significant improvement in 
the CPRS subscale of thought disturbances 
in 6 Patients on Propranolol within two 
weeks of therapy. Recently, Sheppard (1979) 
has reported an improvement in 7 out of 9 
schizophrenics with Propranolol, with an 
improvement in schneiderian symptoms in 
3 patients. Hirsch et al. (1981) have shown 
significant improvements in the ratings of 
thought disorder (P<0.02 and P<0.05) of 
the BPRS with d-propranolol. Improve-
ments in thought disorder have also been 
found related to the dose i.e. the higher the 
dose, the lower the thought disorder score 
(Yorkston et al., 1981). 
Summarizing, in terms of therapeutic 
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results, the various investigations may be 
divided into 2 groups : positive (Atsmon et al., 
1971 ; 1972 ; Folk et al., 1972; Steiner et al ., 
1973; Rackensperger et al., 1976; Yorkston 
et al., 1974; Zersscn, 1976; Yorkston et al., 
1976a, 1976b; Yorkston et al., 1977; Ridges 
1977; Elizur et al., 1979; Belmaker et al., 
1979; Sheppard, 1979; Hanssen et al., 1980 
and Lindstrom and Persson, 1980) and 
negative studies (Stam, 1971; Gardos et al., 
1973; Orzak, 1977; King et al., 1980; Peet 
et al., 1981a; 1981b; Myers et al., 1981). 
However, controlled studies have hitherto 
been scanty (Yorkston et al., 1977; Ridges 
et al., 1977; Elizur et al., 1979; Lindstrom 
and Persson, 1980; King et al., 1980 and 
Peet et al., 198ia and b). Studies using drug 
combinations (Beta blockers and neurolep-
tics) are frought with the problem of attribut-
ing therapeutic superiority to a specific drug 
response and also the increase in plasma levels 
of neuroleptics due to competitive metabo-
lism by beta blockers (Peet et al., 1981b). 
The present pilot investigation sum-
marizes the effect of dl-propranolol on the 
thought disorder scores of 15 schizophrenic 
patients. 
MATERIAL AND METHOD 
Sample : 
The investigation was conducted upon 
15 male patients, who were admitted in the 
Department of Psychiatry, King George's 
Medical College, Lucknow and diagnosed 
as Schizophrenic psychosis by 2 psychiatrists 
independently on the guidelines of I.G.D. 
IX (1977). Their age ranged from 20 to 35 
years (mean 28.4 years) and duration of 
illness between 3 to 24 months (mean 9.63 
months). 60% of the sample had an in-
siduous onset of illness and 40% had a family 
history of schizophrenia in their first degree 
relatives. The diagnostic subtypes included 
6 hebephrenic, 5 paranoid and 4 chronic 
undifferentiated schizophrenics. All were 
in good physical health and detailed in-
vestigations including an EKG were done 
in each case to exclude any case with a 
cardiac condition, bronchial asthma, obst-
ructive pulmonary disease, pheochromo-
cytoma, diabetes mellitus and an established 
history of alcohol or drug abuse prior to 
propranolol therapy. An informed consent 
was obtained in each case. 
Design : 
80 mg. dl-propranolol supplied as tab-
lets was given orally in 4 divided doses. The 
dose was kept at 160 mg/day during the first 
6 days and then increased gradually so as to 
to reach 1920 mg/day by day 17. This dose 
was kept constant till the end of the study 
(day 28). Pulse and blood pressure were 
closely monitored and the drug was with-
drawn gradually if the pulse rate fell below 
55/mt and b.p. below 80/50 mm of Hg, and 
the patient considered a dropout. No con-
commitant medication was permitted during 
the study period. 
Assessment instruments : 
The response of patients to propranolol 
on thought disorder was noted by the change 
in thought disorder (A and B) scores selected 
from the Modified Brief Psychiatric Rating 
Scale (Overall and Goreham, 1962) and 
the Comprehensive Psychopathological Rat-
ing Subscale for patients with schizophrenic 
syndromes (Jacobsson et al., 1978). A Side-
Effects Checklist was also administed. The 
MBPRS was administered at Week 0, 2 and 
4, while the CPRS subscale and side effects 
check-list at weeks 0, 1, 2, 3 and 4. The 
results were expressed by calculating the 
percentage residual scores derived from the 
difference between the initial and final scores 
on the items representing thought disorder. 
RESULTS 
Table-l demonstrates the percentage 
residual scores in terms of improvement on 
the two thought disorder subscales of 
MBPRS. By the end of the 2nd week 20% 
patients had shown an improvement of 51 % 
and more on the scores of thought disorder 
(A). By the end of the 4th week 73% 306  B. B. SETHI & SANJAY DUBE
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TABLE-I—Percentage residual improvement on 
thought disorder (MBPRS) (N = 15) 
TABLE-II—Percentage residual improvement on 
thought disorder (CPUS) (N = 15) 
From 
Worse . 
Same 
Baseline 
• .. 
. 
Improved up to 25% 
t> 
>t 
»> 
26—50% 
51—75% 
>75% 
Thought 
Disorder 
A 
Wk 2 
0 
0 
3 
9 
2 
1 
* 
Wk 4 
0 
0 
0 
4 
6 
5 
Thought 
Disorder 
B** 
Wk 2 Wk 4 
0 0 
0 0 
4 0 
9 4 
2 6 
0 5 
•Thought Disorder A : Conceptual Disorganization, 
Hallucinatory behaviour, Unusual Thought 
Content. 
•Thougnt Disorder B : Blunted Affect, Grandiosity, 
Suspiciousness, Emotional -withdrawal, Motor 
Retardation, Mannerisms & Posturing. 
patients had shown a similar degree of im-
provement on these parameters. For the 
scores of thought disorder (B), the number 
of patients who improved by more than 50% 
by the end of 2nd and 4th weeks were 
13.3% and 73% respectively. No patient 
worsened or remained the same during the 
trial period. 
Table-II demonstrates the percentage 
residual scores in terms of improvement on 
the two thought disorder scates oi GPRS 
subscalc. In terms of improvement 6.7%, 
40%, 73.3% and 86.7% patients showed 
more than 51 % improvement during the 1st, 
2nd, 3rd and 4th weeks respectively on 
Thought Disorder (A). The corresponding 
percentage of patients who showed a similar 
degree of improvement on thought disorder 
(B) subscale during the 4 weeks of therapy 
were 0%, 20%, 60% and 86.7% respectively. 
1 patient showed no change on both thought 
disorder subgroups even at the end of 4 
weeks. However, no patient worsened while 
on propranolol. Duration of therapy and 
increasing dosage were found to be well 
coiTelated with the number of patients 
showing improvement. 
Thought Disorder : Thought Disorder 
A*  B* 
From 
Baseline 
Wk Wk Wk Wk Wk Wk Wk Wk 
12 3 4 12 3 4 
Worse 00000000 
Same 6 3 2 19 3 2 1 
Improve-
ment 
Up to 
25% 4 4 10 2 2 2 0 
Improve-
ment 
Up to 
26-50% 4 4 1 14 7 2 1 
Improve-
ment 
Up to 
51—75% 03520243 
Improve-
ment 
>75% 1 3 6 11 0 1 5 10 
•Thought Disorder : A—Feeling Controlled, In-
coherent Speech, Hallucinations. 
••Thought Disorder : B—Ideas of Persecution. In-
congruence of Affect, Withdrawal, Blank spells, 
Slowaess of Movements, Mannerisms & Post-
uring. 
Table-Ill demonstrates the frequency 
of commonly occurring side effects. The 
commonest side effects were bradycardia 
(33.3%), fatigue (33.3%), weakness (26.7%) 
and abdominal pain (20.0%). Light headed-
ness, nausea, vomiting and diarrhoea occur-
red infrequently (6.7 %). Most of the patients 
experienced side effects of mild intensity but 
for 1 patient who had severe fatigue. There 
was no association between development 
of beta blocking effects and clinical improve-
ment. In addition to the 15 patients in-
cluded in this analysis, 3 patients developed 
severe bradycardia (Pulse<55/minute) and 
were therefore dropouts. EFFICACY OF PROPRANOLOL ON SCHIZOPHRENIC THOUGHT DISORDER 307 
TABLE III—Frequency of commonly occurring side 
effects 
S. no. Side Effects N % 
Cardiovascular : 
1. Bradycardia .. . . 5 33.3 
2. Hypo/hypertension 
3. Cardiac Decompensation 
CM.S. 
4. Light headedness .. .. 1 6.7 
5. Weakness .. .. 4 26.7 
6. Fatigue .. .. 5 33.3 
G.I.T. : 
7. Nausea .. .. 1 6.7 
8. Abdominal Pain .. 3 20.0 
9. Vomiting .. .. 1 6.7 
10. Diarrhoea .. . . 1 6.7 
Respiratory : 
11. Dyspnoea 
12. Rhonchi 
DISCUSSION 
This pilot investigation of propranolol 
on Indian patients suggests that the drug 
possesses anti-psychotic properties as ob-
served by reduction in the scores of schizo-
phrenic thought disorder. Improvement was 
witnessed sometime between the 1st and 2nd 
weeks of therapy at a dose between 480 mg/-
day to 960 mg/day. The improvements were 
more remarkable at a higher dosage i.e. 
1920 mg/day. In studies employing the use 
of propranolol in high doses such as upto 
4,000-5,000 mg/day toxic effects often pose 
a major problem (Atsmon et al., 1971; 1972; 
Yorkston et al., 1974). In this study, a 
gradually increasing dosage schedule has 
enabled a smooth drug administration period 
which was free of fatal or life threatening 
side effects. Although bradycardia was the 
most frequent side effect, it was not serious 
enough to wan-ant a discontinuation of pro-
pranolol except in 3 patients. Furthermore, 
there was no correlation between brady-
cardia and hypotension with remission of 
schizophrenic symptoms as reported by Volk 
et al. (1972) and side effects when severe 
usually developed within the first 72 hours. 
The mean duration of illness in our sample 
was less than 1 year (x=9.63 months) and 
was possibly a factor contributing to the 
better therapeutic outcome. Although the 
present study is an open trial and is subject 
to the error of a personal bias, even double 
blind studies comparing propranolol to a 
potent neuroleptic or placebo is subject to 
certain pitfalls i. e. development of beta 
blockade effects can distinguish the drug 
from placebo and extrapyramidal symptoms 
being conspicuously absent in this group of 
drugs may differentiate the drug from 
neuroleptics. This however, is hard to over-
come. The mechanism of effect of pro-
pranolol continues to be an area of promising 
research and several studies involving bio-
chemical and psychophysiological para-
meters are in progress. Before the results of 
this study can be generalized it would be 
essential to substantiate these results in a 
study using a double blind controlled design 
conducted on a larger sample over a longer 
period of time. It may be that this group of 
compounds might soon be added to our 
armamentarium for the therapy of schizo-
phrenia as a new non-neuroleptic group of 
compounds. Determination of its mechanism 
of action might also help in our under-
standing of the aetiology of schizophrenia. 
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